PMGC Holdings’ Northstrive Biosciences Announces Results From Phase III Of AI-Driven Drug Discovery Program With Strategic Partner Yuva Bios
Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development. NEWPORT BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB ) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences"). Phase III of the parties’ drug discovery program ("Phase III") was designed to biologically validate a focused set of small-molecule candidates sele...
Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism.
Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development.
NEWPORT BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB ) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences").
Phase III of the parties’ drug discovery program ("Phase III") was designed to biologically validate a focused set of small-molecule candidates selected by Yuva Biosciences' proprietary MitoNova™ AI platform.
These candidates were tested in primary human skeletal muscle cells using an in vitro assay measuring ANT1 protein expression.
ANT1 is a mitochondrial protein involved in cellular energy metabolism in skeletal muscle.
The parties’ drug discovery program is focused on identifying candidates that may support the Company's broader development strategy around muscle preservation, including potential applications relevant to muscle health and metabolic stress.
The study in Phase III evaluated a focused set of AI-selected small-molecule candidates.
According to the results package prepared by Yuva Biosciences, four compounds (C1, C2, C3, and C4) increased ANT1 expression, with the strongest candidates demonstrating dose-dependent induction.
Yuva Biosciences’ results report identified C1, C2 and C4 as the strongest and most dose-consistent ANT1 inducers, while C3 also advanced as a candidate based on statistically significant activity at the highest tested dose.